The “PRO”mise and “PRO”gress of PROs in cancer clinical trials
Author:
Affiliation:
1. Department of Surgery, University of California, San Francisco , San Francisco, CA, USA
2. Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center , New York, NY, USA
Publisher
Oxford University Press (OUP)
Link
https://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djae157/58697994/djae157.pdf
Reference18 articles.
1. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study;Laugsand;Health Qual Life Outcomes,2010
2. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium;Coens;Lancet Oncol,2020
3. International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials;Brady;Qual Life Res,2023
4. Neoadjuvant pembrolizumab plus chemotherapy/ adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study;Dent;J Natl Cancer Inst,2024
5. Pembrolizumab for early triple-negative breast cancer. Reply;Schmid;N Engl J Med,2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3